2.99
1.97%
-0.06
前日終値:
$3.05
開ける:
$3.07
24時間の取引高:
14,547
Relative Volume:
0.17
時価総額:
$121.62M
収益:
-
当期純損益:
$-78.92M
株価収益率:
-1.4657
EPS:
-2.04
ネットキャッシュフロー:
$-72.87M
1週間 パフォーマンス:
-5.97%
1か月 パフォーマンス:
-22.14%
6か月 パフォーマンス:
-14.57%
1年 パフォーマンス:
-8.56%
Vigil Neuroscience Inc Stock (VIGL) Company Profile
VIGL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
VIGL | 2.99 | 121.62M | 0 | -78.92M | -72.87M | -2.04 |
VRTX | 449.83 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.11 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.75 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.87 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-03-31 | 開始されました | Mizuho | Buy |
2022-09-16 | 開始されました | Wedbush | Outperform |
2022-08-29 | 開始されました | H.C. Wainwright | Buy |
2022-02-01 | 開始されました | Guggenheim | Buy |
2022-02-01 | 開始されました | Jefferies | Buy |
2022-02-01 | 開始されました | Morgan Stanley | Equal-Weight |
2022-02-01 | 開始されました | Stifel | Buy |
すべてを表示
Vigil Neuroscience Inc (VIGL) 最新ニュース
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Given New $24.00 Price Target at Wedbush - MarketBeat
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Advances Key Clinical Programs - TipRanks
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - GlobeNewswire
abrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully - Simply Wall St
Vigil Neuroscience retains stock target on TREM2 potential - Investing.com
Vigil Neuroscience retains stock target on TREM2 potential By Investing.com - Investing.com Australia
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Victoria Advocate
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors - BioSpace
Quanterix Appoints Ivana Magovčević-Liebisch to Board of Directors - citybiz
Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Point72 Asset Management L.P. Acquires New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Purchased by Ensign Peak Advisors Inc - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Vigil Neuroscience Inc (VIGL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):